Send to a Friend Font Size: Increase Decrease

Viking Global Investors

Viking Global Investors 's Portfolio

Last Updated on 5/16/11 @ 05:55pm

Ticker	# of Shares	Price	Value
	143,085,126	$195.32	$27,947,386,811
	120,000,000	$195.32	$23,438,400,000
	75,238,700	$195.32	$14,695,622,884
GE	7,138,176	$323.11	$2,306,416,048
V	7,140,286	$317.36	$2,266,041,165
	9,798,229	$195.32	$1,913,790,089
MU	4,424,339	$370.30	$1,638,332,732
PM	9,055,492	$169.98	$1,539,252,531
	6,639,199	$195.32	$1,296,768,349
	6,524,565	$195.32	$1,274,378,036
View Additional Portfolio Information »

Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.

Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Mar 2, 2026 08:01AM Rallybio and Candid Therapeutics announce merger agreement
Feb 17, 2026 08:47PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 05:00PM Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A SAIA INC Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A Primo Brands Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: VIKING GLOBAL INVESTORS LP
Feb 17, 2026 04:28PM Form SCHEDULE 13G/A Rallybio Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 12, 2026 04:55PM Form SCHEDULE 13G Veradermics, Inc Filed by: VIKING GLOBAL INVESTORS LP
Jan 13, 2026 07:09PM Form SCHEDULE 13G REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
Dec 30, 2025 06:31PM Form SCHEDULE 13G Chewy, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:58PM Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A REGAL REXNORD CORP Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:57PM Form SCHEDULE 13G/A Fortive Corp Filed by: VIKING GLOBAL INVESTORS LP
Nov 14, 2025 04:44PM Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
Nov 10, 2025 07:19AM Galecto completes Damora acquisition with $285 million funding round
Oct 3, 2025 04:37PM Form SCHEDULE 13G PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
Oct 3, 2025 10:18AM Form D/A Viking Global Equities
Oct 3, 2025 10:16AM Form D/A Viking Global Equities
Oct 3, 2025 10:15AM Form D/A Viking Global Opportunit
Oct 3, 2025 10:13AM Form D/A Viking Global Opportunit
Oct 3, 2025 10:11AM Form D/A Viking Global Equities
Sep 30, 2025 03:25PM Form D Viking Global Opportunit
Sep 30, 2025 03:11PM Form D Viking Global Opportunit
Sep 24, 2025 05:12PM Form SCHEDULE 13G Oruka Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Sep 17, 2025 01:02AM Oruka Therapeutics raises $180 million in private placement
Sep 10, 2025 04:06PM Form SCHEDULE 13G SAIA INC Filed by: VIKING GLOBAL INVESTORS LP
Sep 2, 2025 04:03PM Form N-PX VIKING GLOBAL INVESTORS For: Jun 30
Aug 14, 2025 08:32PM Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Aug 14, 2025 05:35PM Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed